Navigation Links
InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
Date:2/26/2009

Europe will grant regulatory approval based upon this data, in combination with the other efficacy and safety results the company currently intends to submit in support of its NDA and MAA filings. Further analyses of the CAPACITY results will be conducted in the future and additional observations may be made which may lead to material change in the company's current regulatory strategy for pirfenidone, including a decision by the company not to proceed with either or both of its regulatory submissions in the United States and Europe. These analyses and observations will be included in a presentation of the CAPACITY data that the company expects to make at the American Thoracic Society (ATS) in the second quarter of 2009, and/or in a scientific publication.

Other factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 14, 2008 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) the fact that physician prescriptions of Actimmune for the treatment of IPF, an indication for which Actimmune has not been approved by the FDA, have declined significantly following the March 2007 termination of the Phase 3 INSPIRE trial of Actimmune in IPF and the risk that InterMune's revenue will continue to decline as expected; (ii) risks related to regulation by the FDA and other agencies with respect to InterMune's communications with physicians concerning Actimmune for the treatment of IPF; (iii) reimbursement risks associated with third-party payors; (iv) risks related to whether InterMune is able to obtain, maintain and enforce patents and other intellectual property; (v) risks related to significant regulatory, supply and competitive barriers to entry; (vi) risks related to the uncertain, lengthy and expensive clinical developme
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
2. InterMune Announces Issuance of U.S. Patent for ITMN-191
3. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
4. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
5. InterMune to Present at J.P. Morgan Healthcare Conference
6. InterMune to Present at Deutsche Bank Biotech Boston Confab
7. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
8. InterMune to Release Third Quarter 2008 Financial Results on November 6
9. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
10. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
11. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... , 15 septembre 2014 La deuxième ... (IPAW) (semaine internationale sur la sensibilisation au ... Initiative conjointe de la Plasma Protein Therapeutics ... membres , l,IPAW vise à : ... de la collecte du plasma-aphérèse , Reconnaître ...
(Date:9/14/2014)... 2014 UMBC’s Biotechnology Graduate Programs’ ... October 21, 2014, from 12:00 to 1:00 p.m. EDT. ... innovative curriculum and practice-oriented instruction, designed for working professionals. ... help advance their career in the biotechnology industry. , ... , About UMBC’s Biotechnology Graduate Programs, UMBC offers ...
(Date:9/12/2014)... a magnet using an electric field (magnetoelectric memory ... the next-generation technology for information processing and storage. ... effect, due to the coexistence of electric and ... of spontaneous electric and magnetic polarizations is rare ... of the MEM effect. This article briefly reviews ...
(Date:9/12/2014)... September 12, 2014 Today, “The University” ... Indiegogo. , The film, directed by former Charlie ... Shimon Peres, Ashton Kutcher, Will.i.Am, Michio Kaku, and others. ... there’s only one university in the world devoted to ... the lives of a billion people: Singularity University. Matt ...
Breaking Biology Technology:L' International Plasma Awareness Week célébrera les donneurs et braquera les projecteurs sur les maladies rares 2L' International Plasma Awareness Week célébrera les donneurs et braquera les projecteurs sur les maladies rares 3UMBC Biotechnology Graduate Programs’ Virtual Info Session, October 21, 2014 2Documentary Film that Follows Singularity University Students as They Change the World Launches its IndieGoGo Fundraising Campaign 2
... , , , For purification of up to 10 mg ultrapure plasmid , ... for efficient , purification of plasmid DNA , , ... benefits , , ... by 2x CsCl-gradient centrifugation , , ...
... , , , , , ... Svegliati, Michele Luchetti, and Armando Gabrielli , Laboratorio ... Scientifico, Ancona, Italy , , ... GC-rich sequences difficult to amplify by PCR. This article ...
... , , , QIAGEN introduces the ... automated, high-throughput DNA purification , from high-copy plasmids. ... for a lysate clearing step. Plasmid DNA purification is performed using ... procedure. The protocol , is faster and easier ...
Cached Biology Technology:Successful PCR amplification and subcloning of a GC-rich DNA fragment 2Successful PCR amplification and subcloning of a GC-rich DNA fragment 3Successful PCR amplification and subcloning of a GC-rich DNA fragment 4Successful PCR amplification and subcloning of a GC-rich DNA fragment 5DirectPrep 96 Miniprep System for cost-effective, high-throughput plasmid , DNA purification 2DirectPrep 96 Miniprep System for cost-effective, high-throughput plasmid , DNA purification 3DirectPrep 96 Miniprep System for cost-effective, high-throughput plasmid , DNA purification 4
(Date:9/15/2014)... 2014: Globally, cardiovascular disease (CVD) claims 17 million lives ... an additional 9.4 million. 1 New research presented ... Congress in Montpellier, France on September 15, 2014, suggests ... role. , At the Milk and Dairy ... milk and risk for hypertension and CVD was examined ...
(Date:9/15/2014)... available in German . ... the fossil energy carrier natural gas offers a variety ... Nevertheless, a consequent market penetration is still pending because ... Scientists of the Helmholtz Centre for Environ-mental Research (UFZ) ... Members of the IEA Task 37 (Energy from Biogas) ...
(Date:9/12/2014)... , Sept. 12, 2014 Research and ... "Global IC Card Management System Industry Report 2014" ... IC Card Management System Industry Report 2014 is a ... the global IC card management system. The ... definitions, classifications, applications and industry chain structure. The IC ...
Breaking Biology News(10 mins):Dairy consumption linked to lower blood pressure and cardiovascular disease risk 2The biomethane market needs clear frame conditions for further growth 2The biomethane market needs clear frame conditions for further growth 3Global IC Card Management System Industry Report 2014 2
... LSU,s Sibel Bargu, along with her former graduate student Ana ... LSU,s School of the Coast & Environment, has discovered toxic ... the first time. The recent findings were published in the ... journals, the Proceedings of the National Academy of Sciences ...
... dioxide injected deep underground to help fight climate change could ... up levels of contaminants in the water tenfold or more ... scientists. Based on a year-long analysis of core samples ... contamination is real, but there are ways to avoid or ...
... 9, 2010 For Immediate Release Scientists from ... identified for the first time a novel mechanism that ... body,s natural 24-hour physiological cycle. These new findings could ... shift work, and sleep disturbances, but also for disorders ...
Cached Biology News:LSU oceanography researcher discovers toxic algae in open water 2LSU oceanography researcher discovers toxic algae in open water 3Leaking underground CO2 storage could contaminate drinking water 2Scripps Research scientists identify new mechanism regulating daily biological rhythms 2Scripps Research scientists identify new mechanism regulating daily biological rhythms 3
...
Request Info...
... vectors carry the kanamycin resistance gene that ... Spontaneous generation of multiple insertion events can ... of Geneticin Reagent. Pichia transformants are selected ... level of resistance to Geneticin Reagent. The ...
... Synthetic peptide derived from the C-terminal ... Math-2. Specificity: Specific for the ... (positive controls: human U251 A172 IMR-32 ... rat brain homogenates)Storage: Store at -20C ...
Biology Products: